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Introduction
Annually in the United States, kidney cancer affects nearly
32,000 individuals and is responsible for over 12,000 deaths. It
is estimated that 200,000 individuals are living with kidney can-
cer in the U.S. If kidney cancer is detected and treated early and
the tumor is localized to the kidney, patients can have a good
disease-specific survival rate (95% at 5 years). However, when
patients present with advanced disease, they have only an 18%
two-year survival rate (Linehan et al., 2003). Over the past 20
years, there have been major advances in our understanding of
the epidemiology, pathology, genetics, and treatment of renal
cell carcinoma.
Epidemiology
Since the mid 1970s, kidney cancer has increased at a rate of
about 2.5%/year in the United States. The highest rates of
increase were observed in African Americans. Multiple case
control studies have been performed to identify risk factors for
the development of renal carcinoma. Cigarette smoking, hyper-
tension/antihypertensive medications, obesity, and family histo-
ry (see below) are the major risk factors that have been
identified for the development of renal carcinoma. The popula-
tion attributable risk for hypertension was 21%, for excess
weight was 21%, and for was smoking 18%. At least 40% of the
renal cancer cases were not explained by the risk factors stud-
ied (McLaughlin and Lipworth, 2000).
Studies of dominantly inherited, epithelial forms of renal
carcinoma
In a small proportion of cases, the predisposition to renal carci-
noma occurs as a dominantly inherited, autosomal trait. Rare
familial renal cancers have been studied intensively for clues to
the pathogenesis of the more common, sporadic forms of renal
carcinoma. To date, four types of inherited epithelial forms of
renal carcinoma have been delineated clinically, and genes
responsible for them have been characterized by positional
cloning. Each disease has distinct clinical characteristics, and is
caused by mutation in a distinct gene. There are family pedi-
grees that suggest that other types of dominantly inherited kid-
ney tumors remain to be identified (Teh et al., 1997).
von Hippel Lindau: Clear cell renal carcinoma
Individuals affected with von Hippel Lindau (VHL) are at risk for
the development of tumors in a number of organs, including the
kidneys, pancreas, adrenal glands, brain, spine, eye, and inner
ear. VHL patients are at risk for the development of bilateral,
multifocal, early onset kidney tumors and cysts.The tumors are
uniformly of clear cell histologic type, and the walls of the renal
cysts have clear cell linings. Allelic loss of VHL has been
detected in these renal cysts, and they are thought to be pre-
neoplastic (Lubensky et al., 1996). Often, renal tumors grow
from the cells that line the renal cysts. It has been estimated
that VHL patients are at risk for the development of up to 600
clear cell renal neoplasms and 1100 cysts per kidney (Walther
et al., 1995). These tumors are malignant, can metastasize,
and may appear as early as the second decade of the patient’s
life. Historically, 35%–45% of VHL patients have died of
metastatic renal carcinoma.
Identification of the VHL gene, germline mutations, and
genotype phenotype correlations
The VHL gene was identified by positional cloning in 1993 (Latif
et al., 1993). Complete and partial VHL gene deletions,
frameshift, and missense mutations were found to lead to the
development of VHL (Zbar et al., 1996). Von Hippel-Lindau dis-
ease is classified into distinct clinical subtypes based on the
presence or absence of pheochromocytoma, and the presence
or absence of renal carcinoma (Zbar et al., 1996).
Constitutional chromosome 3 translocation: A unique
model of inherited VHL gene-associated clear cell RCC
In 1979, Cohen et al. reported a family carrying a constitutional
balanced translocation (t[3;8] [p 14;q24]) who had a high risk of
developing bilateral, multifocal clear cell renal carcinoma
(Cohen et al., 1979). In the tumor tissue from the patients in the
3;8 translocation family, the translocated chromosome 3 was
lost, and in 2 of the 4 t(3;8)-associated renal tumors, somatic
VHL mutations were found (Schmidt et al., 1995). Koolen et al.
reported another chromosome 3 translocation (t[2;3] [q34;q21])
family with multiple members with multifocal clear cell kidney
cancer (Koolen et al., 1998). Analysis of the VHL gene in the
kidney tumors revealed somatic mutations in four of five tumors
tested (Bodmer et al., 1998). In an analysis of 10 chromosome 3
translocation families, Geurts van Kessel et al. found a substan-
tial increase in risk of renal cell carcinoma in carriers of recipro-
cal chromosome 3 translocations (Geurts van Kessel et al.,
1999).
VHL gene pathway: Opportunity for disease-specific
approaches to therapy
When the VHL gene was identified, it was a unique gene with
unknown function. Since that time, considerable progress has
been made to elucidate its function (Jaakkola et al., 2001;
Maxwell et al., 1999, 2001; Kaelin, 2003; Ivan et al., 2001;
Iliopoulos et al., 1995). The VHL protein forms a complex with
elongins C and B, Cul-2, NEDD8, and Rbx1 to target the α sub-
unit of the hypoxia-inducible factors (HIF1α and HIF2α) for ubiq-
uitin mediated degradation (Duan et al., 1995; Kibel et al., 1995;
Pause et al., 1997; Kamura et al., 1999; Stickle et al., 2004;
Kaelin, 2002; Pugh and Ratcliffe, 2003a). This is a hypoxia-reg-
ulated process; under normoxic conditions, the HIF complex is
degraded, whereas in hypoxia, HIF1 and HIF2 are not degrad-
ed, and they accumulate (Kaelin, 2003; Pugh and Ratcliffe,
2003b). The interaction between the pVHL E3 ligase complex
and the HIF α subunits is preceded by enzymatic prolyl hydrox-
ylation of HIF, which is the oxygen-sensitive step in the degra-
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dation pathway (Jaakkola et al., 2001; Ivan et al., 2001;Yu et al.,
2001). Two interfaces have been described for VHL: the α
domain interacts with elonginC-elonginB (Stebbins et al., 1999),
and the β domain interacts with HIF (Ohh et al., 2000).
Mutations in the α domain prevent assembly of the VHL-
elonginC-elonginB-Rbx1 complex; mutations in the β domain
inhibit binding and degradation of HIF (Stebbins et al., 1999;
Ohh et al., 2000). Mutations of the VHL gene in either the α or β
domain result in accumulation of HIF, even in normoxic condi-
tions. Increased accumulation of HIF results in increased tran-
scription of a number of genes, including VEGF, EGFR, TGFα,
Glut 1, and PDGF (Figure 1).
Role of VHL in tumorigenesis
Studies have shown that competing the VHL complex from
binding to HIF proteins results in tumorigenesis (Maranchie et
al., 2002), and that mutations in the oxygen-dependent domain
(the VHL binding site) of HIF2α, but not HIF1α, result in tumori-
genesis in xenograft models (Maranchie et al., 2002; Kondo et
al., 2002). Kondo et al. and Zimmer et al. showed that inhibition
of HIF2α is sufficient to suppress pVHL-deficient tumor growth
(Kondo et al., 2002, 2003; Zimmer et al., 2004). These studies
establish that HIF2α is a critical component to tumorigenesis in
clear cell renal carcinoma.
Hereditary papillary renal carcinoma:Type 1 papillary RCC
Hereditary papillary renal carcinoma (HPRC) is an autosomal
dominant hereditary cancer syndrome in which affected individ-
uals are at risk for the development of bilateral, multifocal, type
1 papillary renal carcinoma (Zbar et al., 1994). It is estimated
that HPRC patients are at risk for the development of up to
3,400 tumors per kidney (Ornstein et al., 2000). In contrast to
the other forms of epithelial renal carcinoma, in HPRC, the dis-
ease manifestations are confined to the kidney.
The HPRC gene was shown to be the proto-oncogene, c-
Met, located on the long arm of chromosome 7 (Schmidt et al.,
1997). Met is a cell surface receptor tyrosine kinase for the lig-
and hepatocyte growth factor. Activating mutations in the tyro-
sine kinase domain of Met were found in the germline of
affected individuals in HPRC kindreds. These germline muta-
tions in the MET gene were located in codons homologous to
those mutated in tyrosine kinases that cause other human dis-
eases (Schmidt et al., 1998). Met mutations have also been
found in a subset of tumors from patients with sporadic, type 1
papillary renal carcinoma (Schmidt et al., 1999).
Birt-Hogg-Dubé: Chromophobe and oncocytic renal cell
carcinoma
Birt-Hogg-Dubé (BHD) is a hereditary cancer syndrome in
which affected individuals are at risk for the development of
cutaneous fibrofolliculoma, pulmonary cysts, and pneumotho-
rax and renal tumors (Zbar et al., 2002). 82% of BHD patients
have pulmonary cysts, and 22% have a history of pneumotho-
rax. Kidney tumors occur in 15%–25% of BHD patients and can
be bilateral and multifocal. In the NCI series, 33% of BHD kid-
ney tumors are chromophobe renal carcinoma, 50% are onco-
cytic renal carcinoma, 9% are clear cell, and 6% oncocytoma.
The BHD gene was located on the short arm of chromo-
some 17, and shown to be a novel gene without structural simi-
larities to known genes (Schmidt et al., 2001; Nickerson et al.,
2002). Germline mutations of the BHD gene were identified in
?80% of BHD kindreds. The BHD gene contains a homonu-
cleotide tract, a set of 8 cytosines in exon 10, that is a hot spot
for germline mutations. About 50% of BHD families studied have
a germline insertion or deletion of a single cytosine residue at
the cytosine homonucleotide tract. Virtually all germline muta-
tions in the BHD gene are predicted to truncate the BHD pro-
tein, folliculin.
Hereditary leiomyomatosis renal cell carcinoma
Hereditary leiomyomatosis renal cell carcinoma (HLRCC) is a
hereditary cancer syndrome in which affected individuals are at
risk for the development of cutaneous and uterine leiomyoma
and kidney cancer (Launonen et al., 2001). Toro et al. reported
that a high percentage of women with cutaneous leiomyomas
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Figure 1. Kidney cancer is not a single disease, it is made up of a number of
different types of cancer that occur in the kidney
These different types of kidney cancer are characterized by different his-
tologies, have different clinical courses, respond differently to therapy, and
are associated with alteration of different genes. Modified from Linehan et
al. (2003).
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(98%) have uterine leiomyomas (mean age of diagnosis: 30
years) and that 91% of the women with cutaneous and uterine
leiomyomas had undergone either a hysterectomy or uterine
myomectomy (Toro et al., 2003). The renal tumors that develop
in patients affected with HLRCC have a characteristic histologic
appearance, similar to type 2 papillary renal carcinomas and
collecting duct carcinomas of the kidney.
The gene for HLRCC is the Krebs cycle enzyme fumarate
hydratase (FH) (TMLC, 2002), which has the characteristics of
a tumor suppressor gene. Inactivating mutations have been
found in the germline, and LOH has been detected in HLRCC-
associated kidney tumors (Kiuru et al., 2001). Studies are cur-
rently underway to determine how inactivation of the Krebs
cycle enzyme fumarate hydratase leads to the development of
kidney cancer.
Principles derived from the study of inherited renal
carcinomas
The studies of inherited renal carcinomas emphasize the genet-
ic and biologic diversity of inherited epithelial tumors of the kid-
ney. Of the four renal carcinoma genes identified, three (VHL,
BHD, and FH) are tumor suppressor genes, and one (Met) is a
proto-oncogene. The MET gene encodes a transmembrane
receptor tyrosine kinase, the fumarate hydratase gene carcino-
ma gene encodes a Krebs cycle enzyme, and the VHL gene
regulates the degradation of a transcription factor (HIF).
Although the clinical and pathologic phenotypes associated
with germline alterations of these genes are distinct, recent
studies suggest that the downstream pathways may overlap.
For example, Pennacchietti et al. discovered that hypoxia
induces c-Met (Pennacchietti et al., 2003). Eng et al. have
raised the provocative notion of a renal tumorigenesis pathway
in which severe energy deficits from impaired mitochondrial
function and creation of large amounts of oxygen free radicals
are important for promoting cellular growth and the develop-
ment of renal neoplasia (Eng et al., 2003).
Epidemiologic and family studies suggest the presence of
renal carcinoma susceptibility genes
Epidemiology studies of renal carcinoma have suggested that a
family history of renal carcinoma is a risk factor for the disease.
The relative risk to a sibling of a patient affected with renal can-
cer is estimated at 2.5. This observation was reproducible in a
number of epidemiologic studies. Of particular interest are the
studies of renal carcinoma in the Sweden Family-Cancer
Database, which includes all Swedes born since 1931 and their
biological parents. Hemminki analyzed this database followed
up to year 2000 and observed that risks between siblings were
particularly high for renal cancer. Relative risk to siblings greater
than the relative risk in parent/child pairs suggested to
Hemminki the contribution of a recessive gene(s) to the devel-
opment of sporadic renal carcinoma (Hemminki and Li, 2004a,
2004b).
Investigators in Iceland performed a comprehensive study
of all patients in Iceland who had developed kidney cancer
between 1955 and 1999 (1078 RCC cases). Utilizing an exten-
sive computerized database containing geneologic information
on over 600,000 individuals in Iceland over the past 11 cen-
turies, they were able to conduct a unique analysis to determine
the familial nature of “sporadic” kidney cancer.The results of this
study revealed that nearly 60% of patients in Iceland during this
time period had a first or a second degree relative with kidney
cancer (Gudbjartsson et al., 2002).
There have been reports of non-VHL, non-HPRC kidney
cancer families (Teh et al., 1997; Woodward et al., 2000). Czene
and Hemminki identified 71 families in Sweden in which both a
parent and an offspring had kidney cancer (Czene and
Hemminki, 2002). In population-based studies, kidney cancers
have been associated with other types of cancers, including
prostate cancer (Benichou et al., 1998).
Sporadic kidney cancer
VHL gene mutation and LOH is found in a high percentage of
tumors from patients with noninherited clear cell kidney cancer,
suggesting a tumor suppressor role for the VHL gene (Gnarra et
al., 1994).When the VHL gene was placed in VHL−/− kidney can-
cer cells, tumorigenicity in xenograft models was suppressed
(Kaelin and Maher, 1998), further supporting a tumor suppres-
sor role for VHL (Figure 2).
Although the Met gene has been found to be mutated in a
subset of sporadic type 1 papillary renal carcinomas (Schmidt
et al., 1999), the genes responsible for the majority of sporadic
type 1 papillary, type 2 papillary, and chromophobe renal carci-
noma have yet to be determined. A type of papillary renal 
carcinoma associated with translocations involving the X chro-
mosome (Xp11.2) has been described (Shipley et al., 1995) in
which there is a fusion to the TFE3 transcription factor (PRCC-
TFE3, NONO-TFE3, ASPL-TFE3, PSF-TFE3) (Weterman et
al., 1996; Clark et al., 1997). These studies suggest that a dys-
regulated fusion protein may be central to the neoplastic
process in this malignancy. This tumor, which often occurs in
children, has also been associated with abnormality of the
TFE3-related family member, TFEB, which was recently 
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Figure 2. Molecular targeting of the VHL path-
way in clear cell renal carcinoma
Mutation of the VHL gene in clear cell kidney
cancer results in increased accumulation of HIF
and the resulting increase in transcription of
downstream targets such as VEGFR, EGFR, and
TGFα (A). Mutation of the VHL gene in the α
domain (shown here) inhibits binding to elongin
C and formation of the VHL complex (Stebbins
et al., 1999). Mutation in other parts of the gene,
such as the β domain, prevents binding to and
ubiquitin mediated degradation of HIF (Ohh et
al., 2000). Potential disease-specific therapeutic
approaches include agents which block the
function of HIF (B), VEGFR, or EGFR (C). Modified
from Linehan et al. (2002, 2003).
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cloned in a pediatric papillary renal carcinoma (Davis et al.,
2003).
Conventional and experimental treatment of sporadic
kidney cancer
Laparoscopic nephrectomy is the current therapy for patients
with tumors greater than 4 centimeters, regardless of histologic
type; partial nephrectomy is recommended for patients with
smaller tumors. Treatment with Interleukin-2 (IL-2), the current
FDA-approved agent for patients with advanced renal carcino-
ma, is associated with a complete response in 10% and partial
response in 11% of patients. IL-2 therapy is usually only recom-
mended for patients with clear cell renal carcinoma (Yang et al.,
2003b).
Experimental treatment for advanced renal carcinoma
includes stem cell transfusions from HLA-compatible siblings
following immunoablative chemotherapy (Childs et al., 2000),
treatment with anti-VEGF antibody (Yang et al., 2003a), and
vaccination with autologous tumor cells. Recent meeting
reports indicate encouraging results from agents with c-Raf and
VEGFR inhibitory properties (M.J. Ratain et al., 2004, J. Clin.
Oncol., abstract), VEGFR inhibitors (SU11248) (R.J. Motzer et
al., 2004, J. Clin. Oncol., abstract), and combinations of agents
which target both the VEGFR and EGFR pathways (J.D.
Hainsworth et al., 2004, J. Clin. Oncol., abstract).
Another potential therapeutic approach involves interac-
tions of the molecular chaperone HSP90 and its client proteins.
HSP90 stabilizes a number of client proteins, including HIF1α,
EGFR (the receptor for TGFα), and c-Met. Geldanamycin is an
HSP90 antagonist which has been shown to promote efficient
ubiquitination and proteosome-mediated degradation of HIF1α
in RCC in both normoxia and hypoxia (Isaacs et al., 2002).
Clinical trials are underway to evaluate the effect of gel-
danamycin analogs 17-allylamino-17-demethoxygeldanamycin
(17AAG) and 17-dimethylaminoethylamino-17-demethoxygel-
danamycin (17-DMAG) in patients with kidney cancer.
A number of approaches are under study to block the signal
transduction pathway in c-Met associated tumors, such as
blockade of kinase activation with small molecule inhibitors of
ATP binding, blocking the interaction between activated c-Met
and its downstream signaling molecules, and blockade of the
HGF-Met interactions (Linehan et al., 2003; Kong-Beltran et al.,
2004; Zhang et al., 2004; Michieli et al., 2004).
Targeting single gene pathways
Detailed study of kidneys in VHL and HPRC patients reveals
that patients affected with VHL are at risk for the development of
up to 600 tumors per kidney and that affected HPRC patients
are at risk for the development of up to 3,400 tumors per kidney
(Walther et al., 1995; Ornstein et al., 2000). BHD patients are at
risk to develop hundreds of microscopic oncocytic tumors
(Pavlovich et al., 2002).These findings plus the studies showing
suppression of tumorigenesis of VHL−/− RCC cell lines by (1)
replacement of the VHL gene (Iliopoulos et al., 1995) or (2) inhi-
bition of HIF2α (Kondo et al., 2003; Zimmer et al., 2004) sug-
gest that abnormality of a single gene may be critical for the
development of these tumors and provide rationale for strate-
gies targeting a single gene pathway.
Summary
Kidney cancer is not a single cancer; it is made up of a number
of different types of cancer, with different histologies and differ-
ent clinical courses, responding to different forms of therapy,
and each associated with alteration of a different gene.
Understanding the genetic basis of kidney cancer provides a
unique opportunity for the development of disease-specific
forms of therapy.
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